On December 5, Senators Warren and Grassley sent a letter to the Acting FDA Commissioner, Brett Giroir, MD, pointing out the fact that the FDA previously announced that over-the-counter (OTC) hearing aid rules would be a priority on their fall 2018 Unified Agenda and they would likely deliver the proposed rules well in advance of the August 2020 statutory deadline. Senators Warren and Grassley note that “it is now December 2019 and we have yet to see these regulations come to fruition.”
Citing the serious nature of hearing difficulties and the related conditions that frequently accompany them, the letter requests that the FDA provide an update on the status of the OTC hearing aid rules and regulations and when the FDA expects to finalize the OTC hearing aid rules no later than December 19, 2019.
Related Posts
Virginia and Arkansas Enact Legislation to Join Audiology Interstate Licensure Compact
Virginia and Arkansas recently enacted legislation making them the 24th and 25th states to join the Audiology and Speech-Language Pathology Interstate Licensure Compact (ASLP-IC). VA HB 2033 and AR SB 91 were signed into law by their respective governors on March 23rd and 24th. Licensees in states that participate in the compact will soon be…
HHS and FTC Announce Expansion of Operations to Tackle Challenges in Cybersecurity, Technology, and Privacy
The Federal Trade Commission (FTC) and the Department of Health and Human Services (HHS) recently announced the expansion of operational areas of their organizations that are dedicated to enforcement of laws and regulations related to technology, privacy, and cybersecurity. On February 17, 2023, the FTC announced the creation of a new Office of Technology to “strengthen the FTC’s ability…
HHS Releases Health-Care Cybersecurity Guide
On March 8, the Department of Health and Human Services (HHS) released a cybersecurity implementation guide to assist public and private health-care sectors prevent cybersecurity incidents. “Cyber incidents pose risks to patient data, intellectual property, scientific or laboratory research, medical manufacturing, and ultimately the ability of health-care organizations to safely serve their patients,” said HHS Deputy Secretary Andrea…
